News | March 24, 2010

Moderate Hypofractionated Treatment with Chemotherapy Shows Low Side Effects

March 24, 2010 - A moderately aggressive hypofractionation schedule can be used along with chemotherapy, with low side effects, according to the first published results from a study on the concurrent use of hypofractionated TomoTherapy radiation treatments and chemotherapy for unresectable locally-advanced non-small cell lung cancer (NSCLC).

The Department of Radiation Oncology at the Universitaire Ziekenhuis (UZ) Brussel in Brussels, Belgium, conducted the trial, results of which were published in the journal Cancer (Volume 116, Issue 1, Pages 241-250, Jan 2010).

Previous studies have shown an increase in the rate of tumor control via either escalating biologically effective radiation dose or the addition of chemotherapy concurrent with the course of radiation. This trial tests the feasibility of dose escalation along with concurrent chemotherapy, taking advantage of the accuracy and dose conformity of helical TomoTherapy treatments in minimizing radiation damage to normal tissues.

The study focused on stage III non-small cell lung cancer. Various strategies have been tried to improve outcomes for later stage lung cancer, including increasing dose by increasing the number of fractions (with conventional fractionation of ~2 Gy/fx), increasing dose by increasing fraction size (hypofractionation of up to ~3 Gy/fx), and using chemotherapy at the same time as radiation ("concurrent" chemotherapy).

Increasing the number of fractions has been shown to be of limited benefit because of the lengthening of the overall treatment course and consequent tumor repopulation. Concurrent chemotherapy with conventional fractionation is the standard of care in the United States, after clinical trials showing improved survival over giving chemo either before or after the course of radiation, but it means that the patient will be more likely to incur side effects for a given radiation dose because of an additive effect. Hypofractionation even without concurrent chemo has been shown to be promising in terms of survival. But researchers found in this study that a moderately aggressive hypofractionation schedule can be used along with chemotherapy, with low side effects.

Tomotherapy said that a larger phase II study being started by UZB will add to the evidence that this mode of treatment is safe and effective.

For the complete study: http://www3.interscience.wiley.com/cgi-bin/fulltext/122684509/HTMLSTART?...

For more information: www.tomotherapy.com

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init